A novel design of antibody-drug conjugates composed of antibodies and semitelechelic HPMA copolymer – drug conjugates are being studied. This design integrates the high specificity of antibody-drug conjugates with advantages of macromolecular therapeutics. The new design increases the drug-to-antibody ratio. Consequently, it has the potential to enhance the treatment efficacy and decrease the off-target toxic effects.
x
